This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Adcetris
  • /
  • Phase 3 Frontline Therapy Trial in Patients With A...
Clinical trial

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

Read time: 1 mins
Last updated:1st Nov 2012
Identifier: NCT01712490

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1334 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Actual Study Start Date: November 1, 2012
Actual Primary Completion Date: April 20, 2017
Estimated Study Completion Date: March 1, 2020

- Experimental:
- Active Comparator: ABVD

Related journal:
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma



Category Value
Date last updated at source 2017-08-01
Study type(s) Interventional
Expected enrolment 1334
Study start date 2012-11-01
Estimated primary completion date 2017-04-20

View full details